Literature DB >> 21430989

Emerging pathogenetic mechanisms of pulmonary arterial hypertension: nitric oxide and more.

Young Dae Kim1.   

Abstract

Entities:  

Year:  2011        PMID： 21430989      PMCID： PMC3053561          DOI： 10.4070/kcj.2011.41.2.58

Source DB:  PubMed          Journal:  Korean Circ J        ISSN： 1738-5520            Impact factor:   3.243


× No keyword cloud information.
  27 in total

1.  A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth.

Authors:  Sébastien Bonnet; Stephen L Archer; Joan Allalunis-Turner; Alois Haromy; Christian Beaulieu; Richard Thompson; Christopher T Lee; Gary D Lopaschuk; Lakshmi Puttagunta; Sandra Bonnet; Gwyneth Harry; Kyoko Hashimoto; Christopher J Porter; Miguel A Andrade; Bernard Thebaud; Evangelos D Michelakis
Journal:  Cancer Cell       Date:  2007-01       Impact factor: 31.743

2.  Nitric oxide synthase generates nitric oxide locally to regulate compartmentalized protein S-nitrosylation and protein trafficking.

Authors:  Yasuko Iwakiri; Ayano Satoh; Suvro Chatterjee; Derek K Toomre; Cecile M Chalouni; David Fulton; Roberto J Groszmann; Vijay H Shah; William C Sessa
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-14       Impact factor: 11.205

3.  The effects of monocrotaline pyrrole on cultured bovine pulmonary artery endothelial and smooth muscle cells.

Authors:  J F Reindel; R A Roth
Journal:  Am J Pathol       Date:  1991-03       Impact factor: 4.307

4.  Aberrant cytoplasmic sequestration of eNOS in endothelial cells after monocrotaline, hypoxia, and senescence: live-cell caveolar and cytoplasmic NO imaging.

Authors:  Somshuvra Mukhopadhyay; Fang Xu; Pravin B Sehgal
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-10-27       Impact factor: 4.733

5.  Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension.

Authors:  A Giaid; D Saleh
Journal:  N Engl J Med       Date:  1995-07-27       Impact factor: 91.245

6.  Functional heterogeneity of bone morphogenetic protein receptor-II mutants found in patients with primary pulmonary hypertension.

Authors:  Ayako Nishihara; Tetsuro Watabe; Takeshi Imamura; Kohei Miyazono
Journal:  Mol Biol Cell       Date:  2002-09       Impact factor: 4.138

7.  Disruption of endothelial-cell caveolin-1alpha/raft scaffolding during development of monocrotaline-induced pulmonary hypertension.

Authors:  Rajamma Mathew; Jing Huang; Mehul Shah; Kirit Patel; Michael Gewitz; Pravin B Sehgal
Journal:  Circulation       Date:  2004-09-07       Impact factor: 29.690

8.  Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marius M Hoeper; Marc Humbert; Adam Torbicki; Jean-Luc Vachiery; Joan Albert Barbera; Maurice Beghetti; Paul Corris; Sean Gaine; J Simon Gibbs; Miguel Angel Gomez-Sanchez; Guillaume Jondeau; Walter Klepetko; Christian Opitz; Andrew Peacock; Lewis Rubin; Michael Zellweger; Gerald Simonneau
Journal:  Eur Heart J       Date:  2009-08-27       Impact factor: 29.983

Review 9.  Cellular and molecular basis of pulmonary arterial hypertension.

Authors:  Nicholas W Morrell; Serge Adnot; Stephen L Archer; Jocelyn Dupuis; Peter Lloyd Jones; Margaret R MacLean; Ivan F McMurtry; Kurt R Stenmark; Patricia A Thistlethwaite; Norbert Weissmann; Jason X-J Yuan; E Kenneth Weir
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

10.  Gene expressions of nitric oxide synthase and matrix metalloproteinase-2 in monocrotaline-induced pulmonary hypertension in rats after bosentan treatment.

Authors:  Hee Sun Koo; Kwan Chang Kim; Young Mi Hong
Journal:  Korean Circ J       Date:  2011-02-28       Impact factor: 3.243
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.